Life Scientist > Health & Medical

ErbB2 research may give key to cancer growth

28 February, 2003 by Melissa Trudinger

Researchers at the CRC for Cellular Growth Factors have determined the structure of ErbB2, providing an important clue in how the molecule may contribute to the uncontrolled growth of cancer cells.


Bionomics, Florey in epilepsy collaboration

26 February, 2003 by Graeme O'Neill

Adelaide biomed company Bionomics (ASX: BNO) has established a strategic research collaboration with the Howard Florey Institute of Experimental Physiology and Medicine that it hopes will speed its development of new drugs for epilepsy and other brain disorders.


HIV vaccine research landscape 'not all doom and gloom'

25 February, 2003 by Graeme O'Neill

New approaches mean there is still hope for an effective HIV vaccine, Australian researchers have said in the wake of today's release of disappointing AIDS vaccine results by US company VaxGen.


WEHI scientist wins Eppendorf research award

21 February, 2003 by Melissa Trudinger

Hamish Scott, of Melbourne's Walter and Eliza Hall Institute of Medical Research, was presented with the Eppendorf Award for Young Australian Researchers at this week's 24th Lorne Genome Conference.


Garvan celebrates 40 years

18 February, 2003 by Iain Scott

Sydney's Garvan Institute of Medical Research yesterday threw a party to celebrate its 40th birthday.


NHMRC guidelines recommend embryo access freeze

14 February, 2003 by Pete Young

A freeze on access by researchers to any human embryo not in storage for at least one year is among proposed official guidelines on the use of embryonic stem cells released this week by the National Health and Medical Research Council (NHMRC).


Takeover bid made for Sirtex

12 February, 2003 by Iain Scott

US company Cephalon has made a $AUD271 million takeover offer for Sydney-based cancer treatment company Sirtex Medical.


Allergan deal paying off for Peplin

11 February, 2003 by Pete Young

The first fruits of anti-cancer drug developer Peplin Biotech's landmark licensing deal with US pharmaceutical company Allergan have surfaced in the form of a 240 per cent surge in Peplin's first-half revenues.


Malaria vaccine at least eight years away, conference told

10 February, 2003 by Graeme O'Neill

Veteran Melbourne malaria researcher Prof Robin Anders believes a malaria vaccine is still at least eight to 15 years away -- but he is optimistic that a vaccine is feasible, and will be effective, despite the phenomenal capacity of the parasite, Plasmodium falciparum, to take evasive action against drugs and vaccines.


New cancer genomics centre opens at Peter Mac

04 February, 2003 by Melissa Trudinger

The new Ian Potter Foundation Centre for Cancer Genomics and Predictive Medicine was opened today at the Peter MacCallum Cancer Institute by Victorian Innovation Minister John Brumby.


VRI happy with H. pylori diagnostic study

03 February, 2003 by Melissa Trudinger

VRI BioMedical's OncoAlert diagnostic test has performed well in a clinical study examining the test's ability to diagnose Helicobacter pylori infections.


Malaria parasite gene targets identified

31 January, 2003 by Graeme O'Neill

A Melbourne-Philadelphia research team has provided a graphic demonstration of the power of genomics and bioinformatics by identifying a host of prospective drug targets in the malaria parasite, Plasmodium falciparum.


Boost for NSW spinal injury research

29 January, 2003 by Susan Williamson

NSW Premier Bob Carr has pledged $AUD10.9 million towards research into spinal injury.


Former telco ventures into biotech with Burnet deal

24 January, 2003 by Melissa Trudinger

Former telecommunications company Select-Tel is the latest to venture into biotech, signing a memorandum of understanding with Melbourne's MacFarlane Burnet Institute for Medical Research and Public Health to commercialise several projects from the Institute.


New genetic theory claims epileptics may cop a double whammy

23 January, 2003 by Graeme O'Neill

Some individuals born into families with a history of epilepsy may be doubly, even triply cursed, according a new theoretical model of the world's most common inherited brain disorder.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd